Duncan McKechnie

Executive Vice President and Chief Commercial Officer · Vertex Pharmaceuticals

Biopharmaceuticals

Duncan McKechnie leads Vertex Pharmaceuticals’ global commercial organization. His career spans sales and marketing at GlaxoSmithKline, commercial leadership at Novartis, and the development and launch of Vertex’s medicines.

Last reviewed: Nov 2, 2026

Duncan McKechnie

Executive Vice President and Chief Commercial Officer
Vertex Pharmaceuticals

Last Reviewed: November 2, 2026

Executive Summary

Duncan McKechnie leads Vertex Pharmaceuticals’ global commercial organization. His career spans sales and marketing at GlaxoSmithKline, commercial leadership at Novartis, and the development and launch of Vertex’s medicines.

Career Highlights

  • Became Vertex chief commercial officer on July 1, 2025.
  • Led North American commercial operations during the launches of Trikafta, Casgevy, Alyftrek and Journavx.
  • Joined Vertex in 2013 after commercial assignments at Novartis and GlaxoSmithKline.

Professional Journey

McKechnie began his pharmaceutical career at GlaxoSmithKline after completing his university studies. He spent nine years in sales and marketing roles in the United Kingdom before moving to Novartis, where he worked for more than thirteen years across the United Kingdom, Switzerland and United States.

At Novartis, he served as vice president of cardiovascular marketing from November 2008 to March 2012. His subsequent responsibilities included brand maximization and established medicines, alongside responsibility for the respiratory franchise during part of 2013. These assignments preceded his move to Vertex in June 2013 as vice president of global marketing.

At Vertex, he led global commercial strategy, working with research, clinical development and regulatory colleagues on the cystic fibrosis portfolio. His work included launch planning, research-asset priorities and the alignment of clinical development and health-economics plans.

In October 2018, McKechnie became senior vice president and head of North America commercial. He oversaw marketing, sales, market access and patient support in the United States and Canada. That team supported the launches of Trikafta, Casgevy, Alyftrek and Journavx. In 2022, he also assumed responsibility for global health economics, pricing and market access across Vertex’s portfolio.

He became executive vice president and chief commercial officer in July 2025. The role broadened his commercial remit worldwide, covering activities supporting the approved use of the company’s marketed medicines.

Education

McKechnie earned a degree in business studies from the University of Plymouth in the United Kingdom.